" I've actually spoken to investigators who participated in the Osiris study, and they reckon that the principal reason that the product failed was Osiris' lack of understanding of the underlying mechanics of how/why the cells work. Consequently, the trial design was sub-optimal "..
Yes - this is also my understanding....you need to joins the dots now and work out why MSB proceeded to spend $50M on Osiris (outside the significant check-mate patent protection ). Silviu's knowledge of regenerative medicine (including the Adelaide scientists) and FDA background (trials) could be one reason, the other reason may be explained by ASX release 28/4/14.
As you would know Randall Mills (former Osiris CEO) is no longer at the company.
Please DYOR and do your own thing.
" I've actually spoken to investigators who participated in the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |